Pheon Therapeutics
- Sector
- Biotech
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 10 pending · first 2024
- Rank in peer group#397 of 1449
Capital timeline
No federal awards or Form D filings are on record for this company.
Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.
Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards
Founder? Add funding contextStanding among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 2 granted of 12- GrantedANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED BENZO[e]PYRIDO[1,2-a][1,4]DIAZEPINESUSPTOUS 12,583,857
- PendingAntibody-drug ConjugatesUSPTOApplication 18994490
- PendingCytotoxic AgentsUSPTOApplication 17954152
Show all 12 patent records
- ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED BENZO[e]PYRIDO[1,2-a][1,4]DIAZEPINESMar 24, 2026 · US 12,583,857Granted
- Antibody-drug ConjugatesJan 29, 2026 · Application 18994490Pending
- Cytotoxic AgentsApr 4, 2024 · Application 17954152Pending
- Anti-proliferative Agents Comprising Substituted Benzo[e]pyrido[1,2-a][1,4]diazepinesFeb 27, 2024 · US 11,912,700Granted
- Asymmetric Conjugate CompoundsJan 4, 2024 · Application 18066137Pending
- G-a Crosslinking Cytotoxic AgentsMar 31, 2022 · Application 17426492Pending
- Polycyclic Amides As Cytotoxic AgentsDec 2, 2021 · Application 17273098Pending
- Asymmetric Conjugate CompoundsMay 16, 2019 · Application 16189310Pending
- Cytotoxic CompoundsApplication 19138593Pending
- Antibody Drug Conjugates That Bind CDCP1 And Uses ThereofApplication 18994498Pending
- Cytotoxic CompoundsApplication 63387426Pending
- Antibodies To Cub Domain-containing Protein 1 (CDCP1) And Uses ThereofApplication 19138599Pending
Related companies, and why
- Socrates Biosciences IncSimilar federal contract value in Biotech · null in contracts
- STONESTABLE, INC.Similar federal contract value in Biotech · null in contracts
- CICLOMED, LLCSimilar federal contract value in Biotech · null in contracts
- SCARAB GENOMICS LLCSimilar federal contract value in Biotech · null in contracts
- Ambros TherapeuticsSimilar federal contract value in Biotech · null in contracts
- EXESALIBERO, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .